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ABSTRACT
Objective To investigate how the type and number of 
long- term conditions (LTCs) impact on all- cause mortality 
and major adverse cardiovascular events (MACE) in people 
with rheumatoid arthritis (RA).
Design Population- based longitudinal cohort study.
Setting UK Biobank.
Participants UK Biobank participants (n=502 533) aged 
between 37 and 73 years old.
Primary outcome measures Primary outcome measures 
were risk of all- cause mortality and MACE.
Methods We examined the relationship between LTC 
count and individual comorbid LTCs (n=42) on adverse 
clinical outcomes in participants with self- reported RA 
(n=5658). Risk of all- cause mortality and MACE were 
compared using Cox’s proportional hazard models adjusted 
for lifestyle factors (smoking, alcohol intake, physical 
activity), demographic factors (sex, age, socioeconomic 
status) and rheumatoid factor.
Results 75.7% of participants with RA had multimorbidity 
and these individuals were at increased risk of all- cause 
mortality and MACE. RA and >4 LTCs showed a threefold 
increased risk of all- cause mortality (HR 3.30, 95% CI 
2.61 to 4.16), and MACE (HR 3.45, 95% CI 2.66 to 4.49) 
compared with those without LTCs. Of the comorbid LTCs 
studied, osteoporosis was most strongly associated with 
adverse outcomes in participants with RA compared 
with those without RA or LTCs: twofold increased risk of 
all- cause mortality (HR 2.20, 95% CI 1.55 to 3.12) and 
threefold increased risk of MACE (HR 3.17, 95% CI 2.27 to 
4.64). These findings remained in a subset (n=3683) with 
RA diagnosis validated from clinical records or medication 
reports.
Conclusion Those with RA and other LTCs, particularly 
comorbid osteoporosis, are at increased risk of adverse 
outcomes, although the role of corticosteroids could not 
be evaluated in this study. These results are clinically 
relevant for the monitoring and management of RA across 
the healthcare system, and future clinical guidelines for RA 
should acknowledge the importance of multimorbidity.
INTRODUCTION
Rheumatoid arthritis (RA) is a debilitating, 
chronic autoimmune disease characterised 
by inflammation of the synovial joints. RA 
is associated with physical and socioeco-
nomic issues, including increased pain levels, 
reduced physical functioning and early 
mortality.1–4 Globally, while disability adjusted 
life years for RA have improved since 1990, 
age- standardised prevalence and incidence 
rates are increasing.5
Between 60% and 75% of those with RA 
are reported to have multimorbidity—two 
or more long- term conditions (LTCs)—
with higher number of LTCs reported with 
increasing age and disease activity.6–8 Common 
comorbidities include cardiovascular condi-
tions9 such as coronary artery disease10 and 
cardiac failure,11 as well as mental health 
conditions such as depression.12 Cardiovas-
cular disease accounts for the majority of the 
excess mortality observed in RA, with raised 
inflammatory markers and shared risk factors 
implicated.13 However, the effects of comor-
bidities in RA have generally been studied in 
isolation and less is known regarding the risks 
Strengths and limitations of this study
 ► This is the first study to examine both comorbidity 
and multimorbidity in rheumatoid arthritis (RA) and 
the associations with mortality and major adverse 
cardiovascular events.
 ► We used data from 5658 participants in UK Biobank 
with RA, including detailed information on partici-
pant demographics, lifestyle factors and rheumatoid 
factor status to examine multimorbidity and comor-
bidity using 42 non- RA long- term condition.
 ► These results provide crucial new information which 
should be incorporated into clinical guidelines and 
used to influence management of peoples with RA.
 ► This study was limited by lack of information on RA 
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posed by multimorbidity when RA co- occurs with more 
than one other long- term physical or mental health LTC.
Through analysis of UK Biobank data, this paper aims 
to explore the effect of multimorbidity and a wide range 
of comorbid LTCs on all- cause mortality and major 
adverse cardiovascular events (MACE) in people with RA. 
Our objectives were to:
1. Compare the effect of LTC count on all- cause mortality 
in those with and without self- reported RA.
2. Compare the effect of LTC count on MACE in those 
with and without self- reported RA.
3. Evaluate the effect of individual comorbid LTCs on the 
risk of all- cause mortality and MACE in participants 
with self- reported RA.
PATIENTS AND METHODS
Study design and data collection
This study used data from UK Biobank, a longitudinal 
population- based cohort of 502 533 participants, aged 
37–73 years in Great Britain.14 UK Biobank baseline data 
were collected between 2006 and 2010 from recruitment 
centres in Scotland, England and Wales, and subsequently 
linked to mortality and hospitalisation outcomes from 
external routine data registries over a median follow- up 
period of 9 years. A subset of primary care data was avail-
able for 230 105 participants.
Variables and outcome measures
UK Biobank collected information on a wide range of 
demographic, health- based lifestyle and self- reported LTC 
questions through self- administered touch screen ques-
tionnaire and nurse- led interview. These include age, sex, 
socioeconomic status (measured using Townsend score, a 
UK area- based measure of deprivation),15 smoking status, 
frequency of alcohol intake, body mass index (BMI), level 
of physical activity and number of LTCs.
The age range of the study population was 37–73 years 
and was categorised into groups: 37–49, 50–59 and 60–73 
years. Sex was a binary categorical variable. Smoking 
status was categorised into ‘never’ or ‘current or previous’. 
Frequency of alcohol intake was categorised into four 
groups, ‘Never or special occasions only’, ‘One to three 
times a month’, ‘One to four times a week’ or ‘Daily or 
almost daily’. BMI was categorised into four groups based 
on WHO BMI guidelines16: ‘underweight <18.5’, ‘normal 
weight 18.5–24.9’, ‘overweight 25–29.9’ and ‘obese ≥30’. 
Level of physical activity was defined as ‘none’, ‘low’, 
‘medium’, or ‘high’ using Metabolic Equivalent Task 
scores data based on International Physical Activity Ques-
tionnaire scoring protocol (available from https:// sites. 
google. com/ site/ theipaq/ scoring- protocol) which has 
shown moderate to good validity and reliability in adults 
in UK settings.17 18
Rheumatoid factor was ascertained, as part of a 
predefined biomarker panel, for all participants in UK 
Biobank, regardless of diagnosis, and categorised into 
positive and negative status, with rheumatoid factor 
<20 IU/mL considered negative, and values above this 
considered positive (by manufacturer specification, avail-
able at https://www. beckmancoulter. com/ wsrportal/ 
techdocs? docname=/ cis/ 988646/%/ RF_ 988646-% 25% 
25_ English. pdf). Participants whose rheumatoid factor 
was labelled as ‘not reportable at assay (too low)’ were 
considered to be rheumatoid factor negative. Similarly, 
those labelled ‘not reportable at assay (too high)’ were 
considered rheumatoid factor positive.
The list of 42 LTCs considered was based on previous 
work in UK Biobank,19 20 the number of LTCs reported, 
apart from RA, were summed and then categorised as 0, 
1, 2–3 and ≥4 LTCs. RA and all LTCs in UK Biobank are 
based on self- report using a questionnaire and nurse- led 
interview asking for existing diagnoses.
All- cause mortality was calculated using data linkage to 
national mortality registers. MACE were calculated using 
stroke and myocardial infarction hospitalisation event 
data from UK Biobank, and using International Classifi-
cation of Diseases, 10th revision (ICD-10) mortality codes: 
‘I00- I78’, ‘G45’, ‘G451- G454’, ‘G456’, ‘G458’, ‘G459’, 
and ‘G460- G468’. The median follow- up time for both 
morality and MACE was 9 years; the length of follow- up 
for each participant varied as follow- up continued until 
an event occurred (death or MACE) or until the mortality 
the linkage was carried out.
A sensitivity analysis of self- report RA by participants was 
performed by examining four other indicators of RA: any 
primary care RA Read code, any secondary care RA hospi-
talisation code, self- reporting of any common RA drugs 
or any primary care prescription record of RA drugs (as 
shown in online supplemental table 1). Both prospec-
tive and retrospective data were used: primary care Read 
codes were available for a maximum period of January 
1991 and December 2017, and primary care prescriptions 
were between January 1991 and December 2016; the time 
period for each participant varied, depending on records 
held. Participants were considered to have confirmed RA 
if they had a positive record for one or more of these indi-
cators. This analysis was performed on a subset (74%) of 
participants who self- reported RA for whom primary care 
data in UK Biobank was available (n=4196/5658).
Statistical methods
In line with previous UK Biobank studies, χ2 tests were 
used for both categorical data and ordinal data. Kruskal- 
Wallis tests were used for continuous data.21 Similarly, 
we used χ2 testing to examine differences in proportion 
of individual LTCs between those with and without RA. 
Age- adjusted Cox’s proportional hazards tests were used 
to examine the relationship between LTC count/type 
of LTCs with all- cause mortality and MACE as outcome 
variables in those with and without RA. The model 
was further adjusted for demographic, lifestyle and 
biological factors (sex, Townsend score, alcohol status, 
smoking status, BMI, physical activity and rheumatoid 
factor status) as described above. Among those with RA, 
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to display proportion of events (all- cause mortality or 
MACE) in participants with 0, 1, 2–3 and ≥4 comorbid 
LTCs. To measure the contribution of individual index 
LTCs towards all- cause mortality and MACE in those with 
and without RA, we created a categorical variable that 
assigned participants to one of four groups: those with 
neither RA nor the index condition (reference group), 
those with RA but not the index LTC (RA only), those 
with no RA with the index LTC (index LTC only), and 
those with both RA and the index LTC. This variable was 
used as an outcome measure in an age- adjusted Cox’s 
proportional hazards model controlling for demographic 
factors, lifestyle factors and rheumatoid factor status. To 
calculate whether there was a multiplicative or syner-
gistic effect between RA and each index LTC, we used 
an analysis of variance (ANOVA) to compare the p alues 
between two Cox’s proportional hazards models: the 
first contained RA and the index LTC, and the second 
contained RA, the index LTC and a statistical interaction 
term between RA and the index LTC. A statistical inter-
action was considered significant when the ANOVA test 
has a p<0.01.
RESULTS
5658 UK Biobank participants (1.1%) reported having 
RA. Lifestyle and demographic characteristics of partic-
ipants with and without self- reported RA are shown in 
table 1. Participants with RA were significantly more likely 
to be older, women, have lower socioeconomic status, be 
current or previous smokers, have a lower frequency of 
alcohol intake, have a BMI ≥30, have lower levels of phys-
ical activity and have larger numbers of comorbid LTCs. 
χ2 testing showed participants with self- reported RA were 
significantly more likely to have rheumatoid factor posi-
tive status: 35.6% had rheumatoid factor levels of over 20 
IU/mL—compared with 3.6% in those without RA.
Prevalence of LTCs in people with RA
Proportions of number of LTCs in participants with and 
without RA are shown in table 1. Reporting multiple LTCs 
was more common in those with RA: 34.5% had 2–3 LTCs 
(27.1% in those without RA), and 11.1% had ≥4 LTCs 
(4.9% in those without RA). Overall, 75.7% of people 
with RA were noted to be multimorbid. The difference 
in comorbidity experienced by those with and without 
RA is shown in online supplemental table 2). Those with 
RA reported proportionately higher numbers of physical 
and mental health- based LTCs, namely: cardiovascular 
LTCs including hypertension, coronary heart disease 
and stroke or transient ischaemic attack; pulmonary 
LTCs including asthma, chronic obstructive pulmonary 
disease (COPD) and chronic bronchitis; digestive system 
LTCs including dyspepsia, irritable bowel syndrome and 
inflammatory bowel disease; musculoskeletal conditions 
including osteoporosis; and mental- health based LTCs 
including depression.
Table 1 Demographic factors, lifestyle factors, number 
of long- term conditions and rheumatoid factor status in 






Mean age (years 
(SD)); missing 
values=0 (0%)
59.3 (7.1) 56.5 (8.1)
Age (years); missing values=0 (0%)
  37–49 675 (11.9%) 117 209 (23.6%)
  50–59 1800 (31.8%) 165 359 (33.3%)
  60–73 3183 (56.3%) 214 314 (43.1%)
Sex; missing values=0 (0%)
  Female 3952 (69.8%) 269 452 (54.2%)
  Male 1706 (30.2%) 227 430 (45.8%)
Townsend score; missing values=623 (0.12%)
  0–20 (least 
deprived)
998 (17.7%) 99 665 (20.1%)
  20–40 980 (17.4%) 99 117 (20%)
  40–60 1087 (19.2%) 99 311 (20%)
  60–80 1154 (20.4%) 99 224 (20%)
  80–100 (most 
deprived)
1429 (25.3%) 98 952 (19.9%)
Smoking status; missing values=2950 (0.59 %)
  Never 2625 (46.8%) 270 916 (54.8%)
  Current or previous 2983 (53.2%) 223 066 (45.2%)
Frequency of alcohol intake; missing values=1502 (0.30 %)
  Never or special 
occasions only
1830 (32.4%) 96 832 (19.5%)
  One to three times 
a month
690 (12.2%) 55 170 (11.1%)
  One to four times 
a week
2315 (41%) 242 428 (48.9%)
  Daily or almost 
daily
811 (14.4%) 100 962 (20.4%)
BMI (kg/m2); missing values=5820 (1.15%)
  Underweight <18.5 50 (0.9%) 2576 (0.5%)
  Normal weight 
18.5–24.9
1543 (27.9%) 155 896 (31.7%)
  Overweight 25–
29.9
2194 (39.6%) 212 032 (43.2%)
  Obese ≥30 1750 (31.6%) 120 679 (24.6%)
Physical activity; missing values=7156 (1.42 %)
  None 814 (14.8%) 32 035 (6.5%)
  Low 409 (7.4%) 18 531 (3.8%)
  Medium 4111 (74.5%) 389 412 (79.5%)
  High 182 (3.3%) 49 890 (10.2%)
Number of long- term conditions; missing values=1845 (0.36 
%)
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All-cause mortality and LTCs in people with RA
We examined the outcomes associated with different LTC 
counts in participants with RA using a Kaplan- Meier plot 
(see online supplemental figure 1). There was an increased 
proportion of all- cause mortality in participants with RA 
concurrent with increasing multimorbidity counts: 4.2% 
(n=58) in those with no additional LTCs, 5.3% (n=91) in 
those with 1 additional LTC, 9.9% (n=194) in those with 
2–3 additional LTCs and 14.4% (n=90) in those with ≥4 
additional LTCs during the follow- up period (median 9 
years).
To quantify the effect of LTC count on all- cause 
mortality, we performed a Cox’s proportional hazards test 
controlling for lifestyle factors, demographic factors and 
rheumatoid factor in participants with and without self- 
reported RA using a stepwise model adjustment (table 2). 
Participants with RA and no additional LTCs had a signif-
icant increase in all- cause mortality when using an age- 
adjusted Cox’s proportional hazards model fully adjusting 
for additional lifestyle and demographic factors (HR 1.59, 
95% CIs 1.21 to 2.08) compared with those without RA or 
any LTCs. While controlling additionally for rheumatoid 
factor status appeared to show some attenuation of all- 
cause mortality risk, a statistically significant risk for this 
group remained (HR 1.39, 95% CI 1.05 to 1.84) when 
compared with those without RA or any LTCs. When 
examining additional comorbid LTCs alongside RA, there 
appeared to be a dose- based response all- cause mortality 
risk, with a 44% increased risk of all- cause mortality in 
those with RA and one other LTC (HR 1.44, 95% CI 1.14 
to 1.81), an approximately two- and- a- half- fold increased 
risk for RA with 2–3 other LTCs (HR 2.48, 95% CI 2.12 to 
2.90) and an over threefold increased risk associated for 
RA with ≥4 other LTCs (HR 3.30, 95% CI 2.61 to 4.16) 
compared with those without RA or any LTCs in the fully 
adjusted models, which included rheumatoid factor. A 
dose- based response was also observed in the non- RA 
population: those with 1 LTC had a 39% increased risk of 
death (HR 1.39, 95% CI 1.33 to 1.46), and those with ≥4 
were at a two- and- a- half- fold increased risk (HR 2.69 95% 
CI 2.54 to 2.85) compared with participants without RA 
or any LTCs.
MACE and LTCs in people with RA
We next investigated the effect of LTC count on MACE 
in participants with RA using a Kaplan- Meier plot (see 
online supplemental figure 2). For RA and no additional 






  1 1690 (30.0%) 162 657 (32.9%)
  2–3 1943 (34.5%) 134 403 (27.1%)
  ≥4 623 (11.1%) 24 157 (4.9%)
Rheumatoid factor (IU/ml); missing values=33 066 (6.6 %)
  <20 3396 (64.4%) 447 472 (96.4%)
  >20 1879 (35.6%) 16 720 (3.6%)
Unless otherwise indicated, all results are shown as number (%).
Unless indicated, p<0.01. χ2 test was used for categorical 
variables, Kruskal- Wallis test was used for continuous variables.
Table 1 Continued
Table 2 Relationship between long- term conditions and all- cause mortality in participants with and without self- reported 
rheumatoid arthritis (RA) using age- adjusted multivariate Cox’s proportional hazards regression analysis
Risk of all- cause mortality
Comorbidity status 
(reference: no RA 
and no other long- 
term conditions)
Adjusted for sex 
and Townsend 
score HR (95% CI)
Adjusted for sex, 
Townsend score, 
alcohol status and 
smoking status HR 
(95% CI)
Adjusted for sex, 
Townsend score, 
alcohol status, 
smoking status, BMI 
and physical activity 
HR (95% CI)
Adjusted for sex, 
Townsend score, alcohol 
status, smoking status, 
BMI, physical activity and 











No RA 1.45 (1.39 to 1.51) 1.42 (1.36 to 1.48) 1.40 (1.34 to 1.47) 1.39 (1.33 to 1.46) 5785 (3.6%)




No RA 2.03 (1.95 to 2.11) 1.92 (1.84 to 2.00) 1.84 (1.77 to 1.92) 1.83 (1.75 to 1.91) 7914 (5.9%)




No RA 3.39 (3.22 to 3.57) 3.04 (2.88 to 3.20) 2.71 (2.56 to 2.86) 2.69 (2.54 to 2.85) 2605 (10.8%)
RA 4.68 (3.80 to 5.78) 3.95 (3.19 to 4.89) 3.52 (2.81 to 4.40) 3.30 (2.61 to 4.16) 90 (14.4%)
Unless otherwise shown, Cox’s proportional hazards p<0.01.
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event, compared with 4.6% of participants with RA and 
one additional LTC (n=78), 6.7% those with RA and 2–3 
additional LTCS (n=131), and almost four times as many 
proportionately in participants with RA and ≥4 LTCs 
(11.7%, n=73 events) over the follow- up period.
Table 3 shows the risk of MACE for participants with 
and without RA using age- adjusted multivariate Cox’s 
proportional hazards regression models. There was a 
63% increased hazard of MACE for participants with RA 
and no other LTCs compared with participants without 
RA or any LTCs (HR 1.63, 95% CI 1.21 to 2.21) in a fully 
adjusted model including demographic factors, lifestyle 
factors and rheumatoid factor status. This remained signif-
icant for people with RA with increasing LTCs count, with 
an 86% increased risk of MACE in participants with one 
other co- occurring LTC (HR 1.86, 95% CI 1.31 to 2.15), 
an over twofold increase in those with 2–3 co- occurring 
LTCs (HR 2.09, 95% CI 1.73 to 2.54) and an almost three- 
and- a- half- fold increase in MACE for those with ≥4 LTCs 
(HR 3.39, 95% CI 2.61 to 4.40), compared with those 
without RA or any LTCs. This relationship was similar but 
to a lesser degree for participants without RA, with those 
with 1 LTC at 24% increased risk (HR 1.24, 95% CI 1.19 
to 1.31), those with 2–3 LTCs at a 66% increased risk (HR 
1.66, 95% CI 1.59 to 1.74) and those with ≥4 LTCs at over 
two times risk (HR 2.37 95% CI 2.23 to 2.53) of MACE 
compared with those without LTCs.
A similar pattern was observed for the relationship 
between LTC count and mortality/MACE for the group 
without RA (see online supplemental figure 3 and 4).
Contribution of individual LTCs to all-cause mortality and 
MACE in people with RA
Using an age- adjusted Cox’s proportional hazards model, 
adjusting for demographic factors, lifestyle factors and 
rheumatoid factor status, we investigated the role indi-
vidual LTCs play in risk of all- cause mortality and MACE, 
using participants with no RA and no index condition as 
the reference group (tables 4 and 5).
The presence of cardiovascular- based LTCs appeared 
to be a risk factor in those with RA for both all- cause 
mortality and MACE. Compared with those with no RA 
and no hypertension, RA with hypertension showing 
an over one- and- a- half- fold increased risk of all- cause 
mortality (HR 1.59, 95% CI 1.37 to 1.86) and an approxi-
mately twofold increased risk of MACE (HR 2.07, 95% CI 
1.64 to 2.33).
Similarly, heart disease was associated with an over 
twofold increase for both all- cause mortality (HR 2.07, 
95% CI 1.63 to 2.63) and MACE (HR 2.28 95% CI 1.76 
to 2.98) in those with RA compared with those with no 
RA and no heart disease. However, there was no evidence 
of interaction between RA and either cardiovascular 
condition. While thyroid disorders showed no significant 
increased risk of all- cause mortality, they displayed an over 
twofold increased risk of MACE (HR 2.10, 95% CI 1.50 to 
2.93) in those with RA compared with those without RA 
or thyroid disease but again there was no significant inter-
action between RA and thyroid disease and MACE event.
The co- occurrence of osteoporosis in participants with 
RA appeared to strongly influence both mortality and 
MACE; more than doubling all- cause mortality (HR 2.20, 
Table 3 Relationship between long- term conditions and major adverse cardiovascular events in participants with and without 
self- reported rheumatoid arthritis (RA) using age- adjusted multivariate Cox’s proportional hazards regression analysis
Risk of MACE
Comorbidity status 
(reference: no RA 
and no other long- 
term conditions)
Adjusted for sex 
and Townsend 
score HR (95% CI)
Adjusted for sex, 
Townsend score, 
alcohol status and 
smoking status HR 
(95% CI)
Adjusted for sex, 
Townsend score, 
alcohol status, 
smoking status, BMI 
and physical activity 
HR (95% CI)
Adjusted for sex, Townsend 
score, alcohol status, 
smoking status, BMI, 
physical activity and 













1.30 (1.24 to 1.36) 1.28 (1.22 to 1.34) 1.26 (1.20 to 1.320 1.24 (1.19 to 1.31) 4512 (2.8%)






1.86 (1.78 to 1.94) 1.78 (1.70 to 1.86) 1.67 (1.60 to 1.75) 1.66 (1.59 to 1.74) 6208 (4.6%)






3.04 (2.87 to 3.22) 2.76 (2.60 to 2.93) 2.40 (2.26 to 2.56) 2.37 (2.23 to 2.53) 1980 (8.2%)
RA 4.79 (3.79 to 6.04) 4.07 (3.21 to 5.16) 3.52 (2.73 to 4.52) 3.39 (2.61 to 4.40) 73 (11.7%)
Unless otherwise shown, Cox’s proportional hazards p<0.01.
















pen: first published as 10.1136/bm






6 McQueenie R, et al. BMJ Open 2020;10:e038829. doi:10.1136/bmjopen-2020-038829
Open access 
95% CI 1.55 to 3.12), and resulting in an over three times 
higher risk of MACE (HR 3.17, 95% CI 2.17 to 4.64) 
compared with those without RA or osteoporosis. This 
increased risk in those with both RA and osteoporosis 
was greater than in those with RA but no osteoporosis or 
those with osteoporosis but no RA. Interaction terms for 
RA and osteoporosis showed no significant interaction 
with all- cause mortality (p=0.10), suggesting an additive 
effect only, but displayed a significant interaction with 
MACE (p<0.01), suggesting a multiplicative or synergistic 
effect in the association with MACE.
Sensitivity analysis of RA self-report
To investigate sensitivity of self- report by participants 
with RA, we examined the proportion of people with 
any primary care RA Read code, any secondary care RA 
hospitalisation code, self- reporting of any common RA 
drugs and any primary care prescription record of RA 
drugs (see online supplemental table 1) for participants 
who had self- reported RA and had available primary care 
data available in UK Biobank (n=4196). Medications used 
here were previously reported by Siebert et al.21 Using 
this method, we were able to identify RA medications, 
hospitalisations or primary care Read code in 3683 
(87.8%) participants (see online supplemental table 3). 
Analysis performed in this study was repeated in these 
participants and showed the same relationships as those 
reported above in n=5658 with self- report RA, with only 
small changes in HR observed (see online supplemental 
tables 4–8).
DISCUSSION
Within UK Biobank, multiple LTCs was common in 
participants with RA, with approximately 75.7% reporting 
multimorbidity and 45% of participants reporting two or 
more additional LTCs alongside RA. In our fully adjusted 
modes, increasing LTC count was associated with increased 
mortality and MACE in people with RA. When examining 
individual LTCs, we observed hypertension, heart disease, 
osteoporosis and thyroid disorders to increase risk of 
adverse outcomes. Of these, osteoporosis was associated 
with one of the largest increases in both adverse outcomes 
measured: participants with both RA and osteoporosis 
were at over three times the risk of all- cause mortality and 
Table 4 Risk of all- cause mortality for individual index conditions in patients with rheumatoid arthritis (RA) and no index 
condition, RA with index condition, RA with no index condition and RA and index condition




No RA, with index 
condition HR (95% CI)
RA, no index condition HR 
(95% CI)
RA and index 
condition HR (95% 
CI)
Index condition
  Hypertension 1 1.24 (1.21 to 1.28) 1.29 (1.11 to 1.48) 1.59 (1.37 to 1.86)
  Coronary heart disease 1 1.57 (1.50 to 1.65) 1.26 (1.12 to 1.42) 2.07 (1.63 to 2.63)
  Diabetes 1 1.68 (1.60 to 1.75) 1.33 (1.18 to 1.48) 1.83 (1.37 to 2.44)
  Asthma 1 1.10 (1.05 to 1.15) 1.27 (1.13 to 1.42) 1.56 (1.22 to 2.00)
  Dyspepsia 1 1.01 (0.97 to 1.06)* 1.27 (1.14 to 1.43) 1.45 (1.10 to 1.90)
  Cancer 1 2.50 (2.41 to 2.59) 1.35 (1.20 to 1.52) 3.04 (2.39 to 3.86)
  Depression 1 1.27 (1.20 to 1.35) 1.29 (1.15 to 1.44) 1.71 (1.21 to 2.42)
  Thyroid disorder 1 1.05 (0.98 to 1.12)* 1.32 (1.18 to 1.47) 1.14 (0.80 to 1.62)*
  COPD 1 2.11 (1.98 to 2.49) 1.26 (1.13 to 1.42) 2.68 (2.00 to 3.58)
  Epilepsy 1 1.81 (1.42 to 1.82) 1.29 (1.15 to 1.43) 2.86 (1.43 to 5.73)
  Migraine 1 0.85 (0.76 to 0.94) 1.29 (1.16 to 1.44) 1.09 (0.55 to 2.19)*
  Psoriasis/eczema 1 1.05 (0.98 to 1.14)* 1.27 (1.14 to 1.42) 1.88 (1.20 to 2.95)
  Prostate disease 1 0.83 (0.76 to 0.90) 1.30 (1.17 to 1.45) 0.90 (0.43 to 1.90)*
  Osteoporosis 1 1.26 (1.14 to 1.39) 1.25 (1.12 to 1.40) 2.20 (1.55 to 3.12)
  Atrial fibrillation 1 1.40 (1.45 to 1.57) 1.30 (1.17 to 1.45) 1.32 (0.50 to 3.52)*
  Anxiety 1 1.22 (1.10 to 1.35) 1.30 (1.16 to 1.44) 1.48 (0.67 to 3.30)*
  Inflammatory bowel disease 1 1.37 (1.20 to 1.57) 1.30 (1.17 to 1.44) 1.30 (0.54 to 3.11)*
  Heart failure 1 2.69 (2.22 to 3.25) 1.29 (1.16 to 1.43) 5.14 (2.14 to 12.38)
Age- adjusted Cox’s proportional hazards models were adjusted for sex, Townsend score, smoking status, alcohol intake frequency, body 
mass index, physical activity level and rheumatoid factor status. Cox’s proportional hazards p<0·01, except for those labelled with *indicating 
p>0.01. Index conditions labelled ** have interaction term p<0.01.
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two times the risk of compared with those with neither 
LTC. The negative effect of having both RA and osteo-
porosis was particularly evident in MACE outcomes, for 
which there was a significant interaction between RA and 
osteoporosis, suggesting a multiplicative or synergistic 
effect on MACE of having both these conditions together. 
The presence of hypertension or heart disease alongside 
RA increased the risk of mortality and MACE, in keeping 
with previous literature,22 23 but there was no evidence of 
a synergistic effect.
To the best of our knowledge, this paper is the first to 
compare LTC count and type of comorbid LTCs and their 
association with all- cause mortality and MACE in men 
and women with RA after adjusting for a wide range of 
sociodemographic and lifestyle variables along with rheu-
matoid factor status. In our study, increasing LTC count 
resulted in adverse outcomes in participants with RA, with 
an increased rate of all- cause mortality and MACE.
We have shown that multimorbidity is common in 
participants with RA, with around 75% of participants 
with RA reporting one or more additional LTCs. This is 
in agreement with reported comorbidity rates of between 
60% and 75% in those with RA,6–8 although these studies 
typically examined a smaller number of LTCs than in this 
study. We have shown participants with RA and 2–3 other 
LTCs were at over twice the risk of all- cause mortality, 
while those with ≥4 more were over three times the risk 
compared with participants with no LTCs. This data 
provide evidence for the first time the increased risk 
of all- cause mortality in men and women with RA and 
multimorbidity. While previous work has highlighted 
an increased risk of mortality in patients with RA,24 25 or 
specific comorbidities alongside RA—for example, in 
COPD26 and depression27—these studies did not examine 
the effect of LTC count. One matched cohort study used 
a multimorbidity weighted index to study the effect of 
multimorbidity on mortality, but only examined effects 
in women.28 Another examined LTCs using the Charlson 
Comorbidity Index29; however, this measure uses only 
19 LTCs and the study examined only all- cause mortality 
outcomes. Our study is the first study of its type to link 
multimorbidity in RA with MACE outcomes. Existing 
research has highlighted that RA increases the risk of 
cardiovascular events, and that individual LTCs such as 
diabetes and hypertension are risk factors30; however, 
to date, no study has shown an association between 
Table 5 Risk of major adverse cardiovascular events (MACE) for individual index conditions in patients with rheumatoid 
arthritis (RA) and no index condition, RA with index condition, RA with no index condition and RA and index condition
Risk of MACE
No RA, no index 
condition
No RA, with index 
condition HR (95% CI)
RA, no index condition 
HR (95% CI)
RA and index condition 
HR (95% CI)
Index condition
  Hypertension 1 1.50 (1.44 to 1.55) 1.48 (1.25 to 1.75) 1.97 (1.66 to 2.33)
  Coronary heart disease 1 1.89 (1.80 to 1.98) 1.43 (1.45 to 1.63) 2.28 (1.76 to 2.98)
  Diabetes 1 1.67 (1.58 to 1.75) 1.49 (1.31 to 1.69) 1.69 (1.19 to 2.39)
  Asthma 1 1.12 (1.06 to 1.18) 1.43 (1.25 to 1.63) 1.47 (1.09 to 1.98)
  Dyspepsia 1 1.14 (1.08 to 1.20) 1.39 (1.22 to 1.58) 1.85 (1.30 to 2.34)
  Cancer 1 1.11 (1.04 to 1.17) 1.43 (1.26 to 1.62) 1.44 (0.98 to 2.11)†
  Depression 1 1.25 (1.17 to 1.34) 1.39 (1.22 to 1.58) 2.06 (1.41 to 3.00)
  Thyroid disorder 1 1.14 (1.03 to 1.23) 1.37 (1.20 to 1.55) 2.10 (1.50 to 2.93)
  COPD 1 1.49 (1.37 to 1.62) 1.40 (1.24 to 1.59) 1.97 (1.33 to 2.92)
  Epilepsy 1 1.50 (1.30 to 1.73) 1.41 (1.21 to 1.60) 2.21 (0.83 to 5.88)†
  Migraine 1 0.99 (0.89 to 1.12)† 1.40 (1.23 to 1.58) 2.08 (1.12 to 3.87)
  Psoriasis/eczema 1 1.05 (0.96 to 1.14)† 1.42 (1.26 to 1.61) 1.23 (0.64 to 2.37)†
  Prostate disease 1 0.92 (0.83 to 1.00)† 1.41 (1.25 to 1.60) 1.27 (0.64 to 2.54)†
  Osteoporosis* 1 1.34 (1.18 to 1.53) 1.25 (1.10 to 1.41) 3.17 (2.17 to 4.64)
  Atrial fibrillation 1 1.41 (1.25 to 1.60) 1.72 (1.53 to 1.93) 2.67 (1.99 to 5.95)
  Anxiety 1 1.28 (1.14 to 1.43) 1.40 (1.24 to 1.59) 2.73 (1.30 to 5.72)
  Inflammatory bowel disease 1 1.09 (0.92 to 1.29)† 1.42 (1.26 to 1.60) 1.11 (0.36 to 3.44)†
  Heart failure 1 2.64 (2.15 to 3.24) 1.41 (1.25 to 1.59) 3.45 (1.11 to 10.70)†
Age- adjusted Cox’s proportional hazards models were adjusted for sex, Townsend score, smoking status, alcohol intake frequency, body 
mass index, physical activity level and rheumatoid factor status. Cox’s proportional hazards p<0.01, except for those labelled with †indicating 
p>0.01. Index conditions labelled *have interaction term p<0.01.
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multimorbidity and MACE outcomes in people with RA. 
Collectively, the results presented here report for the first 
time the magnitude of adverse outcomes associated with 
multimorbidity in those with RA.
In keeping with previous studies,8 31 we have shown that 
osteoporosis prevalence is increased in those with RA 
compared with those without RA. The results presented 
in this paper, however, are the first to link osteoporosis 
in those with RA to increased risk of adverse outcomes 
and the first to show significant interaction between 
both conditions and MACE outcomes. The reasons for 
this association are not clear and cannot be extrapolated 
from the available data, which does not include factors 
such as disease severity or duration. One possibility may 
be that corticosteroids and RA disease activity play a role: 
corticosteroids are associated with increased prevalence 
of osteoporosis32; people with RA with higher levels of 
disease activity are more likely to receive corticosteroids; 
both corticosteroid use and increased RA disease activity 
are reported to be associated with worse outcomes in 
mortality and MACE.33 34
Our study therefore has several strong clinical impli-
cations. Current National Institute for Health and Care 
Excellence (NICE) guidelines for RA suggest annual 
checks for the development of hypertension, ischaemic 
heart disease, osteoporosis and depression in RA,35 but 
do not highlight the increased risk of the co- occurrence 
of these LTCs with RA nor the risk posed by multimor-
bidity in general. In addition, we have shown a greatly 
increased risk of adverse outcomes in people with osteo-
porosis and RA that merits further investigation.
Our study has several key strengths: UK Biobank is 
a large population- based study with several thousand 
participants reporting RA; the study setting encompasses 
three countries within the UK (Scotland, England and 
Wales); it includes details of participant demographic 
and lifestyle factors as well as rheumatoid factor levels, 
which allowed us to adjust for variables, which have not 
been explored in previous studies.
Our study is limited by self- reporting of RA and LTCs 
by these participants; however, recent studies have shown 
that self- report is a reliable method for reporting RA.36 
In this study, we additionally used four RA indicators 
(any primary care RA Read code, any secondary care RA 
hospitalisation code, self- reporting of any common RA 
drugs and any primary care prescription record of RA 
drugs) to validate self- reported RA. Using this validation 
approach, we found a positive verification rate (partici-
pants self- reporting RA with further RA indicators) of 
87.8% (n=3683). Re- analysis of the subset of participants 
with RA (see online supplemental tables 4–8) who had a 
validated RA report showed only small changes to Cox’s 
proportional hazards models, and observed effects were 
in agreement with the population who self- reported RA. 
This provides confidence in our findings that we are exam-
ining a true RA population. Rheumatoid factor positive 
status in those self- reporting RA (35.6%) was lower than 
expected, however still a significantly higher proportion 
than in the UK Biobank population who did not report 
RA (3.6%). Analysis of rheumatoid factor in those who 
had a validated RA report showed an increased propor-
tion of positive rheumatoid factor (47.6%), but this level 
remained below previously reported proportions in RA 
populations. We were unable to determine the severity or 
duration of RA in participants, or their previous medica-
tions. Participants in UK Biobank are known to be less 
deprived than the wider UK population,37 suggesting that 
the level of multimorbidity reported here, and resulting 
associations are likely to be conservative in nature. Future 
work will examine potential clusters of LTCs that are asso-
ciated with poor health- related outcomes in people with 
RA to try to inform clinical management of patients with 
RA and multiple LTCs.
CONCLUSIONS
Multimorbidity is common in people with RA and is 
associated with increased risk of all- cause mortality and 
MACE. Certain comorbidities such as osteoporosis merit 
specific attention, in view of their association with adverse 
outcomes; it will be important to test whether this associa-
tion is replicated in other datasets and if so, to explore the 
underpinning mechanisms. As multimorbidity has been 
shown here to influence outcomes for those with RA, 
forthcoming work will examine which clusters of LTCs 
most strongly drive this increased risk of poor outcomes. 
Future clinical guidelines for RA should acknowledge the 
importance of multimorbidity when considering manage-
ment planning and patient outcomes.
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